Logo image of VALN

VALNEVA SE - ADR (VALN) Stock Fundamental Analysis

NASDAQ:VALN - Nasdaq - US92025Y1038 - ADR - Currency: USD

7.81  +0.37 (+4.97%)

Fundamental Rating

3

VALN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. VALN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, VALN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year VALN has reported negative net income.
In the past year VALN has reported a negative cash flow from operations.
VALN had negative earnings in each of the past 5 years.
In multiple years VALN reported negative operating cash flow during the last 5 years.
VALN Yearly Net Income VS EBIT VS OCF VS FCFVALN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M

1.2 Ratios

With an excellent Return On Assets value of 3.34%, VALN belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
The Return On Equity of VALN (7.94%) is better than 95.01% of its industry peers.
Industry RankSector Rank
ROA 3.34%
ROE 7.94%
ROIC N/A
ROA(3y)-18.03%
ROA(5y)-13.82%
ROE(3y)-62.44%
ROE(5y)-54.36%
ROIC(3y)N/A
ROIC(5y)N/A
VALN Yearly ROA, ROE, ROICVALN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80

1.3 Margins

VALN has a Profit Margin of 7.53%. This is amongst the best in the industry. VALN outperforms 94.47% of its industry peers.
Looking at the Gross Margin, with a value of 38.74%, VALN is in the better half of the industry, outperforming 76.11% of the companies in the same industry.
VALN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 7.53%
GM 38.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.75%
GM growth 5Y-10.74%
VALN Yearly Profit, Operating, Gross MarginsVALN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 60 -60

More info and screens

3

2. Health

2.1 Basic Checks

VALN does not have a ROIC to compare to the WACC, probably because it is not profitable.
VALN has more shares outstanding than it did 1 year ago.
VALN has more shares outstanding than it did 5 years ago.
VALN has a worse debt/assets ratio than last year.
VALN Yearly Shares OutstandingVALN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
VALN Yearly Total Debt VS Total AssetsVALN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 0.59, we must say that VALN is in the distress zone and has some risk of bankruptcy.
VALN's Altman-Z score of 0.59 is fine compared to the rest of the industry. VALN outperforms 64.88% of its industry peers.
VALN has a Debt/Equity ratio of 0.82. This is a neutral value indicating VALN is somewhat dependend on debt financing.
VALN's Debt to Equity ratio of 0.82 is on the low side compared to the rest of the industry. VALN is outperformed by 78.97% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF N/A
Altman-Z 0.59
ROIC/WACCN/A
WACC8.19%
VALN Yearly LT Debt VS Equity VS FCFVALN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M -200M

2.3 Liquidity

VALN has a Current Ratio of 2.78. This indicates that VALN is financially healthy and has no problem in meeting its short term obligations.
VALN's Current ratio of 2.78 is on the low side compared to the rest of the industry. VALN is outperformed by 68.81% of its industry peers.
A Quick Ratio of 2.25 indicates that VALN has no problem at all paying its short term obligations.
With a Quick ratio value of 2.25, VALN is not doing good in the industry: 73.26% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 2.25
VALN Yearly Current Assets VS Current LiabilitesVALN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

VALN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.90%, which is quite impressive.
The Revenue for VALN has decreased by -44.52% in the past year. This is quite bad
VALN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.34% yearly.
EPS 1Y (TTM)93.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72%
Revenue 1Y (TTM)-44.52%
Revenue growth 3Y11.69%
Revenue growth 5Y6.34%
Sales Q2Q%20.36%

3.2 Future

The Earnings Per Share is expected to grow by 36.05% on average over the next years. This is a very strong growth
Based on estimates for the next years, VALN will show a very strong growth in Revenue. The Revenue will grow by 22.69% on average per year.
EPS Next Y100.62%
EPS Next 2Y14.98%
EPS Next 3Y18.66%
EPS Next 5Y36.05%
Revenue Next Year8.79%
Revenue Next 2Y10.08%
Revenue Next 3Y14.65%
Revenue Next 5Y22.69%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VALN Yearly Revenue VS EstimatesVALN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
VALN Yearly EPS VS EstimatesVALN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VALN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VALN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VALN Price Earnings VS Forward Price EarningsVALN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VALN Per share dataVALN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as VALN's earnings are expected to grow with 18.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.98%
EPS Next 3Y18.66%

More info and screens

0

5. Dividend

5.1 Amount

VALN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALNEVA SE - ADR

NASDAQ:VALN (2/24/2025, 4:10:42 PM)

7.81

+0.37 (+4.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-20 2025-03-20/amc
Inst Owners29.31%
Inst Owner Change-99.92%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap634.16M
Analysts83.08
Price Target16.81 (115.24%)
Short Float %0.05%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.09%
Min EPS beat(2)-44.01%
Max EPS beat(2)52.2%
EPS beat(4)2
Avg EPS beat(4)9.65%
Min EPS beat(4)-44.01%
Max EPS beat(4)72.74%
EPS beat(8)4
Avg EPS beat(8)-33.8%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-6.31%
Min Revenue beat(2)-14.39%
Max Revenue beat(2)1.77%
Revenue beat(4)1
Avg Revenue beat(4)-8.04%
Min Revenue beat(4)-14.39%
Max Revenue beat(4)1.77%
Revenue beat(8)5
Avg Revenue beat(8)25.47%
Revenue beat(12)7
Avg Revenue beat(12)131.76%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.47%
PT rev (3m)1.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.15%
EPS NY rev (1m)122.06%
EPS NY rev (3m)122.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-1.54%
Revenue NY rev (3m)-1.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.64
P/FCF N/A
P/OCF N/A
P/B 2.79
P/tB 3.29
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)-2.17
FCFYN/A
OCF(TTM)-1.84
OCFYN/A
SpS2.96
BVpS2.8
TBVpS2.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.34%
ROE 7.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 7.53%
GM 38.74%
FCFM N/A
ROA(3y)-18.03%
ROA(5y)-13.82%
ROE(3y)-62.44%
ROE(5y)-54.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.75%
GM growth 5Y-10.74%
F-Score3
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 147.88%
Cap/Sales 11.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 2.25
Altman-Z 0.59
F-Score3
WACC8.19%
ROIC/WACCN/A
Cap/Depr(3y)291.07%
Cap/Depr(5y)239.89%
Cap/Sales(3y)14.73%
Cap/Sales(5y)14.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72%
EPS Next Y100.62%
EPS Next 2Y14.98%
EPS Next 3Y18.66%
EPS Next 5Y36.05%
Revenue 1Y (TTM)-44.52%
Revenue growth 3Y11.69%
Revenue growth 5Y6.34%
Sales Q2Q%20.36%
Revenue Next Year8.79%
Revenue Next 2Y10.08%
Revenue Next 3Y14.65%
Revenue Next 5Y22.69%
EBIT growth 1Y2.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year160.39%
EBIT Next 3Y30.6%
EBIT Next 5Y25.83%
FCF growth 1Y20.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.38%
OCF growth 3YN/A
OCF growth 5YN/A